Advancing and building value

Investor Hub

Media

February 24, 2022

Arch Biopartners CEO, Richard Muruve interview, 2022 Venture 50 TMX Recognition

December 15, 2020

Government of Canada Funding to support Phase II Therapeutic Trial

October 15, 2020

Medical research from University of Calgary to treat COVID-19 patients in human trials (original broadcast, CTV website)

Latest Press Releases

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in ...

Full Release

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement offering ...

Full Release

Closes Units for Debt Settlement

TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that ...

Full Release

The Press Releases page is the starting place for recent advances, new patents, corporate filings, information for investors and all progress updates on active clinical trials.

Browse all of the company’s material news releases.
Read the latest releases when they are published here or via email by subscribing to email alerts and news.

Arch Biopartners key stock indicators, price, volume and all historical data.

The Stock Performance page presents the current and historical data for both of the Arch Biopartners securities symbols on the TSX Venture Exchange and the OTCQB Venture Exchange.

The company’s reports and filings include current filings as well as an archive for investors and the public for research and review:

View the complete Arch Biopartners Inc. filings archives at the SEDAR website here .

Advancing and building value

Media and Press Releases

Media

Latest Press Releases

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Arranges Non-Brokered Private Placement

Closes Units for Debt Settlement

The Press Releases page is the starting place for recent advances, new patents, corporate filings, information for investors and all progress updates on active clinical trials.

Stock Data

Arch Biopartners key stock indicators, price, volume and all historical data.

Reports and Filings

The company’s reports and filings include current filings as well as an archive for investors and the public for research and review:

Investor Information

Investor relations contact information, auditor and transfer agent.

Analyst Coverage

Investment Analysts covering Arch Biopartners.

Contact Arch Biopartners

Stay connected!

Get email alerts when news is published

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Arranges Non-Brokered Private Placement

Closes Units for Debt Settlement

Units for Debt Settlement

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Contact Arch Biopartners

Quick Links

Legal

Connect

Mailing Address